Posted by Michael Wonder on 26 Mar 2025
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections in female adults and paediatric patients 12 years of age and older
25 March 2025 - Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
GSK today announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
